Abstract
In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der Heijde scores (SHS) across levels of composite index-defined disease activity following treatment. In this phase-3, double-blind, placebo-controlled trial, 480 bio-naïve patients with active PsA randomly received intravenous golimumab 2 mg/kg (N = 241; week 0, week 4, every 8 weeks [q8w]) or placebo (N = 239; week 0, week 4, week 12, week 20) followed by golimumab (week 24, week 28, q8w) through week 52. Week 24 and week 52 SHS changes in patient subgroups, defined by levels of disease activity as assessed by several composite measures (minimal disease activity [MDA], very low disease activity [VLDA], Psoriatic ArthritiS Disease Activity Score [PASDAS], Disease Activity in Psoriatic Arthritis [DAPsA], Clinical Disease Activity Index [CDAI]), were evaluated post hoc in 474 patients with evaluable radiographic data. Partially (last-observation-carried-forward methodology) and completely (nonresponder methodology) missing data were imputed. Across indices, golimumab-treated patients demonstrated less radiographic pro...Continue Reading
References
Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Jan 1, 1992·Arthritis and Rheumatism·D M van der HeijdeL B van de Putte
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Jun 1, 1995·Arthritis and Rheumatism·D T FelsonV Strand
Oct 3, 2003·Rheumatology·D KaneO FitzGerald
Apr 9, 2005·Arthritis and Rheumatism·J S SmolenUNKNOWN ATTRACT Study Group
Jul 28, 2006·Arthritis and Rheumatism·William TaylorUNKNOWN CASPAR Study Group
Sep 30, 2006·Arthritis and Rheumatism·Robert LandewéSaeed Fatenejad
Aug 7, 2007·Best Practice & Research. Clinical Rheumatology·Daniel Aletaha, Josef S Smolen
Apr 29, 2008·Arthritis and Rheumatism·Paul J Healy, Philip S Helliwell
Jul 3, 2008·Annals of the Rheumatic Diseases·J S SmolenUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) S
Jan 17, 2009·Annals of the Rheumatic Diseases·L C CoatesP S Helliwell
Feb 24, 2009·Arthritis Research & Therapy·Georg Schett
Mar 2, 2012·Arthritis and Rheumatism·Arthur KavanaughAnna Beutler
Jul 17, 2012·Annals of the Rheumatic Diseases·Philip S HelliwellJessica A Walsh
Sep 15, 2012·Annals of the Rheumatic Diseases·Carrie L WagnerArthur Kavanaugh
Jul 3, 2013·The Journal of Rheumatology·Dafna D GladmanVinod Chandran
Sep 6, 2013·Immunological Investigations·Pedro P C Souza, Ulf H Lerner
Oct 16, 2013·Arthritis Care & Research·Philip S Helliwell, Arthur Kavanaugh
May 17, 2014·Statistics in Medicine·Abdul J SankohRalph B D'Agostino
Jun 3, 2014·The Journal of Rheumatology·Phillip S HelliwellJaap Fransen
Mar 18, 2015·Arthritis Care & Research·Arthur KavanaughStephen Xu
Aug 14, 2015·Annals of the Rheumatic Diseases·Monika M SchoelsJosef S Smolen
Dec 17, 2015·The Journal of Rheumatology·Laura C Coates, Philip S Helliwell
Apr 22, 2016·Annals of the Rheumatic Diseases·Arthur KavanaughIain B McInnes
Jun 18, 2017·Arthritis Research & Therapy·Alan SucurDanka Grcevic
Aug 15, 2017·Arthritis & Rheumatology·Arthur KavanaughElizabeth C Hsia
Dec 2, 2017·Arthritis & Rheumatology·Laura C CoatesPhilip S Helliwell
Jun 8, 2018·Current Topics in Medicinal Chemistry·Georgia MelagrakiAntreas Afantitis
Dec 1, 2018·Arthritis & Rheumatology·Jasvinder A SinghJames Reston
Jan 5, 2019·Rheumatology·Robert LandewéLaura C Coates
Feb 17, 2019·The Journal of Rheumatology·Arthur KavanaughElizabeth C Hsia
Apr 14, 2019·Arthritis Care & Research·M Elaine HusniElizabeth C Hsia